EZH2 and small cell lung carcinoma: Having determined that EZH2 blockade restores the MHC-I expression in CRACD-inactivated SCLC tumors (Fig. 4g–i), we hypothesized that EZH2 inhibitors suppress CRACD-inactivated SCLC tumorigenesis by reactivating MHC-I-based tumor antigen presentation.